Primary Progressive Multiple Sclerosis -
-25% su kodu BOOKS
Pristatymas per 12-18 d.d.
30 dienų grąžinimo politika
"Why are there no effective treatments for my condition? Why do researchers exclude patients with primary progressive multiple sclerosis from enrolling in clinical trials? Please let me know if you hear of studies that I might be allowed to enter or treatments that I could try for my condition. " Thus, in recent years, the sad lament of the patient with primary progressive MS (PPMS). This variant, often in ... Visas aprašymas
Jums taip pat gali patikti
TOP
The Myth of Normal: Trauma, Illness, and Healing in a Toxic Culture
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
The Checklist Manifesto: How to Get Things Right
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
No Bad Parts: Healing Trauma and Restoring Wholeness with the Internal Family Systems Model
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
On Connection: 'Powerful' MATT HAIG
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
Harrison's Principles of Internal Medicine (Vol.1 & Vol.2)
Stephen Hauser, Joseph Loscalzo, Steven Holland, Dan Longo, J. Larry Jameson, Dennis Kasper, Carol Langford, Anthony Fauci
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
Oxford Handbook of Anaesthesia
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
Maybe You Should Talk to Someone: a therapist, her thearapist, and our lives revealed
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
How Not To Die: Discover the foods scientifically proven to prevent and reverse disease
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
Lifespan: Why We Age - and Why We Don't Have To
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
Vademecum Metabolicum: Diagnosis and Treatment of Inborn Errors of Metabolism Forword by William L. Nyhan, San Diego, USA
Johannes Zschocke, Georg F. Hoffmann
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
Cellular and Molecular Immunology
Sarah Henrickson, Abul K. Abbas, Andrew H. Lichtman, Shiv Pillai
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
Physics, Pharmacology and Physiology for Anaesthetists: Key Concepts for the FRCA
Matthew E. Cross, Emma V. E. Plunkett
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
Pocket Guide to Teaching for Clinical Instructors
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
Oxford Handbook of Critical Care
Andrew Webb, Mervyn Singer, Alice Carter
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
The Wills Eye Manual: Print + eBook with Multimedia: Office and Emergency Room Diagnosis and Treatment of Eye Disease
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
Who Deserves Your Love: How to Create Boundaries to Start, Strengthen or End Any Relationship
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
Vaccinated - dead: Histopathological findings following COVID-19 vaccination
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
Steal Like an Artist: 10 Things Nobody Told You About Being Creative
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
TOP
It Didn't Start with You: How Inherited Family Trauma Shapes Who We Are and How to End the Cycle
-25% su kodu BOOKS
Turime sandėlyje pas mūsų tiekėją
Aprašymas
"Why are there no effective treatments for my condition? Why do researchers exclude patients with primary progressive multiple sclerosis from enrolling in clinical trials? Please let me know if you hear of studies that I might be allowed to enter or treatments that I could try for my condition. " Thus, in recent years, the sad lament of the patient with primary progressive MS (PPMS). This variant, often in the guise of a chronic progressive myelopathy or, less commonly, progressive cerebellar or bulbar dysfunction, usually responds poorly to corticosteroids and rarely seems to benefit to a significant degree from intensive immunosuppressive treatments. In recent years, most randomized clin ical trials have excluded PPMS patients on two counts. Clinical worsening devel ops slowly in PPMS and may not be recognized during the course of a 2-or 3-year trial even in untreated control patients. This factor alone adds to the potential for a type 2 error or, at the very least, inflates the sample size and duration of the trial. In addition, there is mounting evidence that progressive axonal degeneration and neuronal loss (rather than active, recurrent inflammation) may be important components of the pathology in this form of the disease. Although contemporary trials are evaluating whether PPMS patients may benefit from treatment with the ~-interferons and glatiramer acetate, preliminary, uncontrolled clinical experi ence suggests that the results may not be dramatic.
Daugiau informacijos
| Leidėjas | Springer Milan |
|---|---|
| Series | Topics in Neuroscience |
| Išleidimo metai | 2012 |
| Viršelio tipas | Minkšti viršeliai |
| EAN | 9788847022362 |